IQVIA Holdings Inc. IQV

Key data

The business

IQVIA is the biggest company that runs drug trials for hire and the biggest seller of data on what medicines get prescribed. Two businesses under one roof. One, Research & Development Solutions, is a contract research organization: a drugmaker hands it a trial, IQVIA finds the patients, runs the sites, manages the data, and gets paid as the work is delivered over years. Two, Technology & Analytics Solutions, is the old IMS Health franchise: it tracks prescriptions doctor by doctor, postcode by postcode, and sells that back to the drugmakers who need to know where their pills are moving. The moat is the data, decades of prescription records no rival can rebuild, plus the switching cost of being embedded in a multi-year trial nobody swaps vendors on midstream. In 2026 it collapsed three segments into two, folding its sales-force outsourcing arm into the data business.

The numbers

Two engines, one steady and one lumpy. Start with the quarters.

Revenue climbs in a near-straight line; net income does not. The $514M in the fourth quarter of 2025 carried a roughly $0.9B one-time credit and is not run-rate. The honest signal is the top line, which reaccelerated to 8.7% year over year in the second quarter of 2026 after a long stretch nearer 4%. That reacceleration answers the open question this name was left with a month ago, whether the bookings slowdown that had been capping how fast signed trials convert into revenue was finally easing: the number says it is starting to. Profit still fell 3.8% that quarter, because interest expense now runs near $197M a quarter and margins are flat, not rising.

Across five years revenue compounded about 4% a year while diluted earnings per share compounded roughly 12%. The gap is the whole model. Net income sat at $1.36B to $1.37B for three straight years, dead flat, yet earnings per share rose from $7.29 to $7.84, because the share count fell about 7%. This is a slow grower that manufactures a double-digit earnings line by buying back stock. The free cash flow behind it is real, $2.1B last year, a 5.9% yield, and it funds the repurchase.

The catch sits in the last two rows. This is a levered rollup: net debt runs about four times EBITDA and interest covers only three times over. On top of the buyback the company spent $1.8B on acquisitions last year, so the debt is a choice, not a wound, but it is why a demand downturn would bite harder here than the flat revenue line suggests. What this memo believes the market underrates: the earnings power sits trapped behind that interest line, and if rates ease while the top line holds, the same operating profit drops far more of itself to the bottom. The print that settles it is quarterly interest expense turning down while revenue growth holds above mid-single digits.

Management

Bousbib has run this since 2012 and built it by merger, Quintiles into IMS, and he keeps buying. The capital record is better than the leverage first suggests: the 2025 buyback ran at an average $186 a share against today's $268, well-timed, though the 2021 through 2024 repurchases at $209 to $233 look ordinary now. Pay is $28M for the chief executive, a rich absolute number but only 2% of net income. The tell that gives pause is the insider selling: ten sales, no buys, over the past year, and Bousbib himself sold about $24M the day after the second-quarter print, near the high. The filings here do not mark which sales were preset 10b5-1 plans, so read the timing, not the intent.

How it fails or surprises you

The funding tap. IQVIA's new work depends on biotech staying funded. If venture and public biotech financing stays tight into 2027, R&D bookings and book-to-bill slip below one, the backlog stops growing, and the reacceleration just seen reverses within a few quarters. The first print to watch is quarterly bookings and the book-to-bill ratio; under 1.0 for two quarters is the tell.

The interest line. Revenue grew 8.7% and profit still fell. That is the fact this memo's optimism explains least well. With net debt near four times EBITDA, every quarter operating leverage fails to show is a quarter the buyback, not the business, carries earnings per share. If rates stay high and margins stay flat, the 12% earnings growth halves.

The data re-rate (right tail). The prescription-data and analytics arm is the hidden asset. If drugmakers pay up for real-world evidence and AI-built analytics, that segment reaccelerates to double digits at margins well above the trials business, and the whole company re-rates from a levered CRO to a data compounder. The print is technology and analytics organic growth pulling clear of the trials line.

Closing thoughts

This is an uncertainty a named print resolves, wrapped inside a re-rating that has mostly already happened. The stock ran from $154 to $268 in a year and sits a hair below its high, so the easy money, the recovery from fear, is made. From here the multiple does little work; earnings have to actually compound, which means the interest line has to stop eating the operating gains. The fatter tail is the downside, not because the business is fragile but because the balance sheet is levered into a demand cycle that can turn, and the market is paying a middling-to-full multiple as if it will not. Call the odds roughly even, and that is judgment, not arithmetic.

The bet stays what it was: drug companies keep handing IQVIA their trials and keep buying its prescription data. It breaks if biotech funding dries up and bookings turn down while the debt still has to be served. The one pair that tells you first is quarterly book-to-bill against quarterly interest expense: the first shows whether the work is still coming, the second whether the earnings it implies can reach the bottom line.